Keyword: Abbott Laboratories
Abbott has received European approvals for two devices designed for children and infants with life-threatening heart defects.
Abbott and Sanofi are partnering up to develop tools that connect their respective blood sugar tracking and insulin delivery technologies.
Ayala Pharmaceuticals has hired AbbVie’s former vice president of oncology, Gary Gordon, M.D., Ph.D., as its new chief medical officer.
Abbott has begun its first randomized, pivotal trial to test a new method of fixing leaky tricuspid heart valves.
Abbott received FDA approval for an addition to its Alinity line of diagnostic hardware designed to screen blood and plasma donations.
Procyrion will advance its heart failure pump through a pilot study and toward a pivotal trial.
Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.
Abbott found that the system was able to significantly reduce hemoglobin A1c levels among patients who take multiple insulin injections per day.
Abbott pledged to provide its neuromodulation tech for the public-private NIH research effort.
The latest generation of Abbott’s market-leading MitraClip device for repairing leaky heart valves was approved with newly flexible steering, navigation and positioning capabilities, for more precise placement during the minimally invasive procedure.